JP2019528693A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528693A5 JP2019528693A5 JP2019510849A JP2019510849A JP2019528693A5 JP 2019528693 A5 JP2019528693 A5 JP 2019528693A5 JP 2019510849 A JP2019510849 A JP 2019510849A JP 2019510849 A JP2019510849 A JP 2019510849A JP 2019528693 A5 JP2019528693 A5 JP 2019528693A5
- Authority
- JP
- Japan
- Prior art keywords
- complex
- amino acid
- peptide
- seq
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 36
- 125000003275 alpha amino acid group Chemical group 0.000 claims 34
- 206010009944 Colon cancer Diseases 0.000 claims 10
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 230000002265 prevention Effects 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 229940122985 Peptide agonist Drugs 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102100022144 Achaete-scute homolog 2 Human genes 0.000 claims 5
- 101000901109 Homo sapiens Achaete-scute homolog 2 Proteins 0.000 claims 5
- 102000002689 Toll-like receptor Human genes 0.000 claims 4
- 108020000411 Toll-like receptor Proteins 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 241000283070 Equus zebra Species 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102000000763 Survivin Human genes 0.000 claims 3
- 108010002687 Survivin Proteins 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 230000035699 permeability Effects 0.000 claims 3
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 claims 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- 101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 claims 1
- 101100452137 Homo sapiens IGF2BP3 gene Proteins 0.000 claims 1
- 101000801539 Homo sapiens Mitochondrial import receptor subunit TOM34 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims 1
- 102100037920 Insulin-like growth factor 2 mRNA-binding protein 3 Human genes 0.000 claims 1
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 1
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims 1
- 102100033583 Mitochondrial import receptor subunit TOM34 Human genes 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 108010008707 Mucin-1 Proteins 0.000 claims 1
- 239000012270 PD-1 inhibitor Substances 0.000 claims 1
- 239000012668 PD-1-inhibitor Substances 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000012737 microarray-based gene expression Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 1
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2016072475 | 2016-09-21 | ||
| EPPCT/EP2016/072475 | 2016-09-21 | ||
| PCT/EP2017/073954 WO2018055060A1 (en) | 2016-09-21 | 2017-09-21 | Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528693A JP2019528693A (ja) | 2019-10-17 |
| JP2019528693A5 true JP2019528693A5 (cg-RX-API-DMAC7.html) | 2020-11-05 |
| JP7346291B2 JP7346291B2 (ja) | 2023-09-19 |
Family
ID=60037562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510849A Active JP7346291B2 (ja) | 2016-09-21 | 2017-09-21 | 癌を治療するための細胞透過性ペプチド、マルチエピトープ、及びｔｌｒペプチドアゴニストを含む融合体 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20190255165A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3515476B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7346291B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102879364B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109963585B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017331949B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3031170A1 (cg-RX-API-DMAC7.html) |
| CL (3) | CL2019000694A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3515476T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2983085T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE067838T2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL265479B (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019002968A (cg-RX-API-DMAC7.html) |
| PL (1) | PL3515476T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018055060A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016146143A1 (en) | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| CA3010779A1 (en) | 2016-03-16 | 2017-09-21 | Amal Therapeutics Sa | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine |
| DK3515476T3 (da) | 2016-09-21 | 2024-09-02 | Amal Therapeutics Sa | Fusion der omfatter et cellepenetrerende peptid, en multiepitop og en trl-peptidagnost til behandlingen af cancer |
| CN110650750A (zh) | 2017-04-04 | 2020-01-03 | 阿维迪科技公司 | 基于肽的疫苗、其制造方法及其用于诱导免疫应答的用途 |
| US12121573B2 (en) | 2019-07-14 | 2024-10-22 | Tianxin Wang | Methods and agents including STING agonist to treat tumor |
| TW202028224A (zh) * | 2018-09-17 | 2020-08-01 | 德商英麥提克生物技術股份有限公司 | B*44限制肽在抗癌免疫治療的用途和相關方法 |
| JP2022536695A (ja) * | 2019-06-12 | 2022-08-18 | ビオンテック ユーエス インコーポレイテッド | 新抗原組成物およびその使用 |
| CN110448689A (zh) * | 2019-08-06 | 2019-11-15 | 太仓美诺恒康生物技术有限公司 | mRNA疫苗及其试剂盒、应用 |
| US20220347315A1 (en) * | 2019-11-22 | 2022-11-03 | The University Of North Carolina At Chapel Hill | Methods and compositions for increasing transduction efficiency with cell membrane fusion proteins |
| EP3827840A1 (en) * | 2019-11-29 | 2021-06-02 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Teipp peptide variant and uses thereof |
| CN116249555A (zh) | 2020-05-19 | 2023-06-09 | 勃林格殷格翰国际有限公司 | 用于癌症治疗的结合分子 |
| TW202227126A (zh) * | 2020-09-14 | 2022-07-16 | 德商百靈佳殷格翰國際股份有限公司 | 異源初免加強疫苗 |
| US20220111028A1 (en) * | 2020-10-14 | 2022-04-14 | Boehringer Ingelheim International Gmbh | Combination Of A STING Agonist And A Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist |
| CN113480666B (zh) * | 2021-08-13 | 2024-01-26 | 郑州伊美诺生物技术有限公司 | Ca153融合蛋白及其制备方法和ca153检测质控品或校准品 |
| CN113786481A (zh) * | 2021-09-27 | 2021-12-14 | 深圳市中佳生物医疗科技有限公司 | 一种抗肿瘤疫苗及其制备方法 |
| TW202346363A (zh) * | 2022-03-16 | 2023-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 腫瘤抗原、包含所述腫瘤抗原的化合物及其用途 |
| KR102823824B1 (ko) | 2022-08-10 | 2025-06-24 | 강원대학교산학협력단 | Pde5 억제제 특이적 결합 도메인, 재조합 단백질 및 이의 용도 |
| KR102886457B1 (ko) | 2022-10-14 | 2025-11-18 | 강원대학교산학협력단 | mTOR 억제제 특이적 결합 도메인, 재조합 단백질 및 이의 용도 |
| GB202216453D0 (en) * | 2022-11-04 | 2022-12-21 | Lisziewicz Julianna | Identification of antigens which induce t-cell responses |
| WO2024196664A1 (en) * | 2023-03-17 | 2024-09-26 | University Of Washington | Dna vaccine targeting overexpressed antigens in colorectal cancer |
| JP7723457B2 (ja) * | 2023-07-03 | 2025-08-14 | メスキュージェナシス株式会社 | 細胞膜透過性を有するペプチドおよびそのスクリーニング方法 |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6479055B1 (en) | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
| FR2728904B1 (fr) | 1995-01-04 | 1997-03-14 | Pasteur Institut | Reactif peptidique permettant de detecter une infection primaire a virus d'epstein-barr par recherche des anticorps correspondants, et procede d'utilisation de ce reactif |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
| US6258782B1 (en) | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
| ES2706547T3 (es) | 1998-12-23 | 2019-03-29 | Pfizer | Anticuerpos monoclonales humanos para CTLA-4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US6750008B1 (en) | 1999-07-09 | 2004-06-15 | Trimeris, Inc. | Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission |
| WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| JP2003520828A (ja) | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート，エルエルシー | Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用 |
| PL209127B1 (pl) * | 2000-02-23 | 2011-07-29 | Smithkline Beecham Biolog | Środek farmaceutyczny do stosowania w immunoterapeutycznym leczeniu raka i sposób diagnozowania u pacjenta obecności lub podatności na raka |
| CA2427858A1 (en) * | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| US20060222656A1 (en) | 2005-04-01 | 2006-10-05 | University Of Maryland, Baltimore | MAGE-A3/HPV 16 peptide vaccines for head and neck cancer |
| AUPR593101A0 (en) | 2001-06-26 | 2001-07-19 | Council Of The Queensland Institute Of Medical Research, The | Cytomegalovirus t cell epitopes |
| US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| GB0218821D0 (en) * | 2002-08-13 | 2002-09-18 | Glaxosmithkline Biolog Sa | Novel compositions |
| PT1558648E (pt) | 2002-10-17 | 2012-04-23 | Genmab As | Anticorpos monoclonais humanos contra cd20 |
| ATE552011T1 (de) | 2003-10-15 | 2012-04-15 | Ist Superiore Sanita | Kolorektal-karzinom-antigen |
| EP1768698A4 (en) | 2004-06-17 | 2009-01-28 | Medimmune Inc | IMMUNOGENIC COMPOSITIONS COMPRISING HMGB1 POLYPEPTIDES |
| SI2287195T1 (sl) | 2004-07-01 | 2019-08-30 | Novo Nordisk A/S | Pan-kir2dl nk-receptor protitelesa in njihova uporaba pri diagnostiki in terapiji |
| MX2007009219A (es) | 2005-02-04 | 2008-01-16 | Survac Aps | Vacuna de peptido de survivina. |
| ES2291071B1 (es) | 2005-06-13 | 2009-03-16 | Proyecto De Biomedicina Cima, S.L. | Agentes y metodos basados en el uso del dominio eda de la fibronectina. |
| EP2133365B1 (en) | 2006-12-27 | 2017-05-17 | Emory University | Compositions and methods for the treatment of infections and tumors |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| WO2008156712A1 (en) | 2007-06-18 | 2008-12-24 | N. V. Organon | Antibodies to human programmed death receptor pd-1 |
| SI2660248T1 (sl) | 2007-07-27 | 2015-10-30 | Immatics Biotechnologies Gmbh | Nova imunoterapija proti možganskim tumorjem |
| KR20100063048A (ko) | 2007-07-31 | 2010-06-10 | 더 존스 홉킨스 유니버시티 | 신생물성 또는 감염성 장애의 면역예방 또는 면역치료를 위한 폴리펩티드-핵산 접합체 |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| WO2009130618A2 (en) | 2008-04-25 | 2009-10-29 | Institute For Systems Biology | Flagellin polypeptide vaccines |
| NO2119726T3 (cg-RX-API-DMAC7.html) | 2008-05-14 | 2015-05-23 | ||
| EP3766517B1 (en) | 2008-06-20 | 2022-11-02 | Duke University | Compositions, methods, and kits for eliciting an immune response |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| KR101040281B1 (ko) * | 2008-08-22 | 2011-06-10 | 가톨릭대학교 산학협력단 | Ｔａｔ-항원 융합단백질과 아쥬번트를 포함하는 백신 조성물 |
| US8074880B2 (en) | 2008-12-01 | 2011-12-13 | Research In Motion Limited | Method, system and mobile device employing enhanced fingerprint authentication |
| TW202442680A (zh) | 2008-12-09 | 2024-11-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| CN102448487B (zh) | 2009-03-16 | 2016-03-16 | 麦克马斯特大学 | 疫苗接种方法 |
| US8916514B2 (en) * | 2009-05-27 | 2014-12-23 | Glaxosmithkline Biologicals, S.A. | CASB7439 constructs |
| MX2012001417A (es) | 2009-07-31 | 2012-07-03 | Organon Nv | Anticuerpos completamente humanos para atenuante de linfocitos b y t (btla). |
| WO2011026122A2 (en) | 2009-08-31 | 2011-03-03 | Amplimmune, Inc. | B7-h4 fusion proteins and methods of use thereof |
| JP5964233B2 (ja) | 2009-09-11 | 2016-08-03 | プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダＰｒｏｙｅｃｔｏ Ｄｅ Ｂｉｏｍｅｄｉｃｉｎａ Ｃｉｍａ， Ｓ．Ｌ． | Ｈｐｖにより惹起される疾患の治療用組成物 |
| US9127077B2 (en) | 2009-09-23 | 2015-09-08 | L'universite Paris Descartes | Polypeptides and nucleic acids for treating ErbB2-dependent cancers |
| MX343747B (es) | 2009-11-24 | 2016-11-22 | Medimmune Ltd | Agentes de union diana contra b7-h1. |
| WO2011101332A1 (en) | 2010-02-16 | 2011-08-25 | Proyecto De Biomedicina Cima, S.L. | Compositions based on the fibronectin extracellular domain a for the treatment of melanoma |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| US9175048B2 (en) | 2010-04-26 | 2015-11-03 | Universite Joseph Fourier | Use of peptides as transporters intended for the internalization of molecules of interest into target cells |
| US9314516B2 (en) | 2010-05-04 | 2016-04-19 | Cassian Yee | Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses |
| EP2449113B8 (en) | 2010-07-30 | 2015-11-25 | CureVac AG | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
| EP4159226A1 (en) | 2010-08-24 | 2023-04-05 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| WO2012035558A2 (en) | 2010-09-14 | 2012-03-22 | Council Of Scientific & Industrial Research | A synthetic immunogen useful for generating long lasting immunity and protection against pathogens |
| US9555074B2 (en) | 2010-10-08 | 2017-01-31 | Regents Of The University Of Minnesota | Annexin II compositions |
| KR101760464B1 (ko) | 2010-10-13 | 2017-07-24 | 사회복지법인 삼성생명공익재단 | 교모세포종의 진단 또는 예후 예측용 바이오 마커 및 그 용도 |
| EP2663367A4 (en) | 2011-01-10 | 2014-08-06 | Cleveland Biolabs Inc | USE OF GREAT-SIMILAR RECEPTOR AGONISTS FOR THE TREATMENT OF CANCER |
| US9187534B2 (en) * | 2011-03-11 | 2015-11-17 | Universite De Geneve | Multi-epitopic vaccine |
| TWI454478B (zh) | 2011-05-13 | 2014-10-01 | Academia Sinica | 類鐸受體-２ 增效劑及其用於刺激免疫反應之用途 |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| EP2756094B1 (en) | 2011-08-15 | 2017-12-27 | Medlmmune, LLC | Anti-b7-h4 antibodies and their uses |
| WO2013067492A1 (en) | 2011-11-03 | 2013-05-10 | The Trustees Of The University Of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
| JP2015500205A (ja) | 2011-11-16 | 2015-01-05 | アムジエン・インコーポレーテツド | 上皮成長因子欠失変異体ｖｉｉｉ関連障害の治療方法 |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| WO2013120073A1 (en) | 2012-02-09 | 2013-08-15 | Av Therapeutics, Inc. | Synthetic toll-like receptor-4 (tlr-4) agonist peptides |
| CN109806387B (zh) | 2012-07-13 | 2022-03-04 | S-目标疗法有限公司 | 免疫调节疫苗 |
| CA2884677C (en) | 2012-09-13 | 2020-06-23 | Universite De Geneve | Cell penetrating peptides derived from the epstein barr virus, compositions and methods thereof |
| PT2897620T (pt) | 2012-09-21 | 2020-09-03 | Intensity Therapeutics Inc | Método de tratamento de cancro |
| WO2014070663A1 (en) | 2012-10-29 | 2014-05-08 | Anderson David E | Compositions and methods for diagnosis and treatment of malignant gliomas |
| AU2014248711A1 (en) | 2013-03-13 | 2015-09-10 | Neostem Oncology, Llc | Individualized high purity colon carcinoma stem cells, methods and use of the same |
| CN106061981A (zh) | 2013-11-06 | 2016-10-26 | 索尔斯蒂斯生物有限公司 | 具有二硫化物基团的多核苷酸构建体 |
| US10206986B2 (en) * | 2013-11-13 | 2019-02-19 | Regents Of The University Of Minnesota | Annexin II variant compositions and methods |
| CA2935214A1 (en) | 2014-01-02 | 2015-07-09 | Memorial Sloan Kettering Cancer Center | Determinants of cancer response to immunotherapy |
| JP2017522046A (ja) | 2014-06-06 | 2017-08-10 | ソルスティス バイオロジクス，リミティッド | 生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物 |
| AU2015338893A1 (en) * | 2014-10-31 | 2017-05-04 | Massachusetts Institute Of Technology | Delivery of biomolecules to immune cells |
| CN106999582A (zh) * | 2014-11-13 | 2017-08-01 | 约翰·霍普金斯大学 | 检查点阻断和微卫星不稳定性 |
| WO2016146143A1 (en) * | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| BR102015025502B1 (pt) | 2015-04-30 | 2022-06-21 | Aegerion Pharmaceuticals, Inc | Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição |
| WO2017002345A1 (ja) | 2015-06-29 | 2017-01-05 | パナソニックＩｐマネジメント株式会社 | 冷蔵庫 |
| GB201520592D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| CN109415703B (zh) | 2016-01-08 | 2024-08-30 | 雷普利穆内有限公司 | 经修饰的溶瘤病毒 |
| JP2019501205A (ja) | 2016-01-11 | 2019-01-17 | ターンストーン リミテッド パートナーシップ | 腫瘍崩壊性ウイルス及びチェックポイント阻害剤の併用療法 |
| CA3010779A1 (en) | 2016-03-16 | 2017-09-21 | Amal Therapeutics Sa | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine |
| EP3455350A4 (en) | 2016-05-09 | 2020-01-15 | Turnstone Limited Partnership | PRIMO-VACCINATION / RECALL POLYTHERAPY |
| PL417980A1 (pl) | 2016-07-16 | 2018-01-29 | Univ Warszawski | Nowe fosfotriazolowe analogi kapu końca 5' mRNA, kompozycja je zawierająca, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA, białka i peptydu |
| WO2018053508A1 (en) | 2016-09-19 | 2018-03-22 | The University Of North Carolina At Chapel Hill | Methods and compositions for inducing an immune response |
| DK3515476T3 (da) * | 2016-09-21 | 2024-09-02 | Amal Therapeutics Sa | Fusion der omfatter et cellepenetrerende peptid, en multiepitop og en trl-peptidagnost til behandlingen af cancer |
| CN118370809A (zh) | 2017-04-03 | 2024-07-23 | 百欧恩泰美国公司 | 蛋白质抗原及其用途 |
| CN111936156A (zh) | 2018-02-02 | 2020-11-13 | 诺华股份有限公司 | 用于治疗癌症的STING激动剂和IL-15/IL15-Ra的组合 |
| CA3110102A1 (en) | 2018-06-20 | 2019-12-26 | Yale University | Rig-i agonists and treatments using same |
| WO2020010451A1 (en) | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| TW202227126A (zh) | 2020-09-14 | 2022-07-16 | 德商百靈佳殷格翰國際股份有限公司 | 異源初免加強疫苗 |
| US20220111028A1 (en) * | 2020-10-14 | 2022-04-14 | Boehringer Ingelheim International Gmbh | Combination Of A STING Agonist And A Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist |
-
2017
- 2017-09-21 DK DK17780656.9T patent/DK3515476T3/da active
- 2017-09-21 HU HUE17780656A patent/HUE067838T2/hu unknown
- 2017-09-21 CN CN201780069631.0A patent/CN109963585B/zh active Active
- 2017-09-21 IL IL265479A patent/IL265479B/en unknown
- 2017-09-21 MX MX2019002968A patent/MX2019002968A/es unknown
- 2017-09-21 US US16/331,398 patent/US20190255165A1/en not_active Abandoned
- 2017-09-21 KR KR1020237029678A patent/KR102879364B1/ko active Active
- 2017-09-21 WO PCT/EP2017/073954 patent/WO2018055060A1/en not_active Ceased
- 2017-09-21 ES ES17780656T patent/ES2983085T3/es active Active
- 2017-09-21 KR KR1020197011382A patent/KR20190057345A/ko not_active Ceased
- 2017-09-21 PL PL17780656.9T patent/PL3515476T3/pl unknown
- 2017-09-21 CA CA3031170A patent/CA3031170A1/en active Pending
- 2017-09-21 JP JP2019510849A patent/JP7346291B2/ja active Active
- 2017-09-21 AU AU2017331949A patent/AU2017331949B2/en active Active
- 2017-09-21 EP EP17780656.9A patent/EP3515476B1/en active Active
-
2019
- 2019-03-18 CL CL2019000694A patent/CL2019000694A1/es unknown
-
2020
- 2020-11-25 US US17/104,786 patent/US11338027B2/en active Active
-
2021
- 2021-06-11 CL CL2021001541A patent/CL2021001541A1/es unknown
-
2022
- 2022-04-12 US US17/718,975 patent/US12220387B2/en active Active
-
2023
- 2023-07-31 CL CL2023002252A patent/CL2023002252A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528693A5 (cg-RX-API-DMAC7.html) | ||
| JP2018509936A5 (cg-RX-API-DMAC7.html) | ||
| JP2018510215A5 (cg-RX-API-DMAC7.html) | ||
| AU2020201896B2 (en) | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | |
| AU2016368433B2 (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
| AU2022268324B2 (en) | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | |
| HRP20200491T1 (hr) | Novi kompleks koji sadrži peptid koji prodire u stanicu, teretni i tlr peptidni agonist za liječenje kolorektalnog karcinoma | |
| AR121587A2 (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer | |
| ES2833162T3 (es) | Receptor de antígeno quimérico y su uso | |
| TW201841934A (zh) | 用於治療癌症免疫治療的新穎肽及其肽組合物 | |
| PE20240778A1 (es) | Nuevos peptidos y combinacion de peptidos para usar en inmuterapia contra el cancer esofagico y otros canceres | |
| US20250312428A1 (en) | Heterologous Prime Boost Vaccine | |
| AU2022204032B2 (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
| Belnoue et al. | Enhancing antitumor immune responses by optimized combinations of cell-penetrating peptide-based vaccines and adjuvants | |
| CN111533796A (zh) | 用于癌症免疫治疗的肽及其肽组合物 | |
| MX2011007963A (es) | Peptidos neil3 y vacunas que incluyen los mismos. | |
| MY166516A (en) | Tomm34 peptides and vaccines including the same | |
| MX2011008917A (es) | Peptidos vangl1 y vacunas que incluyen los mismos. | |
| V. Savvateeva et al. | Prophylactic admission of an in vitro reconstructed complexes of human recombinant heat shock proteins and melanoma antigenic peptides activates anti-melanoma responses in mice | |
| JP2013540419A5 (cg-RX-API-DMAC7.html) | ||
| MX2013004417A (es) | Peptidos wdhd1 y vacunas que los incluyen. | |
| JP2010530748A5 (cg-RX-API-DMAC7.html) | ||
| JP2017500305A5 (cg-RX-API-DMAC7.html) | ||
| US20180028630A1 (en) | Compositions and methods for therapeutic anti-cancer vaccination | |
| Li | Role of heat shock protein in chaperoning tumor antigens and modulating anti-tumor immunity |